Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs S&P500 ETF (SPY) Price & Performance

AstraZeneca plcTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs S&P500 ETF — how do they compare? AstraZeneca plc trades at $158.39 (market cap $248.14B), while S&P500 ETF trades at $772.92. The key difference: AstraZeneca plc pays a 2.01% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AZNSPY
Market Cap
$248.14B
Sector
Health
52-Week High
$209.48$773.22
52-Week Low
$147.06$631.99
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

S&P500 ETF

SPY, the SPDR S&P 500 ETF Trust, trades at $772.90 with minimal daily movement (-0.02%). Technical indicators show a bullish trend with moving averages supporting upside momentum, though oscillators signal potential overbought conditions. The ETF maintains its position as the world's largest fund with approximately $676 billion in assets. Recent news highlights the S&P 500 reaching record highs while facing valuation concerns with the Shiller P/E ratio at 42, the highest since the dot-com era.

The ETF's outlook remains positive with institutional targets pointing toward 8,000 levels, though elevated valuations and weak market breadth present near-term risks. Dividend income continues to attract investors with reliable distributions, but fee comparisons with competing funds highlight cost considerations for long-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY